

June 15, 2023

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001  <b>Company Code No. 524804</b>
--	---

Dear Sir / Madam,

**Sub: Advisory letter from NSE under SEBI (LODR) Regulations, 2015.**

**Ref : Letter No. NSE/LIST/COMP/ AUROPHARMA/01 dated June 14, 2023.**

We inform you that we received the enclosed advisory letter from National Stock Exchange of India Limited advising us to file an update in case of a delay in the timeline for completion of any proposed transaction disclosed to the stock exchanges and to avoid recurrence of such lapses.

This is in connection with the delay in completion of acquisition of 51% stake in GLS Pharma Limited. As per the initial disclosure made on June 18, 2022, the said acquisition was to complete on or before July 31, 2022, but it was completed on August 17, 2022, due to delay in (i) fulfilment of one of the conditions precedents of the acquisition and (ii) credit/transfer of the shares from one of the seller's account to the Company's account. The Stock Exchanges sought a clarification for such delay and necessary clarification was submitted to Stock Exchanges on August 18, 2022.

The Company is also advised to place this advisory letter before its Board of Directors in the ensuing Board Meeting and to disseminate the letter to the Stock Exchanges.

We request you to take the information on record.

Yours faithfully,

**For AUROBINDO PHARMA LIMITED**

B. Adi Reddy  
Company Secretary

Encl: NSE advisory letter dated June 14, 2023.



## National Stock Exchange Of India Limited

Ref: NSE/LIST/COMP/ AUROPHARMA/01

Date: June 14, 2023

To,  
**Aurobindo Pharma Limited**  
Plot No. 2, Maithrivihar,  
Ameerpet, Hyderabad - 500 038,  
Telangana.

**Sub: Advisory letter under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulations').**

Dear Sir/Madam,

This has reference to the disclosure submitted by Aurobindo Pharma Limited ("the Company") on August 18, 2022 w.r.t the completion of acquisition of 51% equity shares in GLS Pharma Limited ("GLS") by the Company.

On June 18, 2022, the Company had intimated the Exchange regarding acquisition of 51% equity shares of GLS wherein the indicative time period for completion of the acquisition was stated to be before July 31, 2022. Further, the Company had intimated the Exchange that the aforesaid acquisition of 51% equity shares of GLS was completed on August 17, 2022 via intimation filed on August 18, 2022.

The Exchange sought clarification from the Company with respect to the reason for delay to provide an update on the extended timeline of acquisition. Company in its reply stated that the delay in completion of the transaction was due to delay in (i) fulfilment of one of the conditions precedent of the acquisition and (ii) credit/transfer of the shares from one of the seller's account to the Company's account.

The Company was required to file an update in case of delay in the timeline for completion of acquisition. It is pertinent to note that when a company files a disclosure informing about an event, all other events in the said matter thereafter would be considered to be material under the provisions of Regulation 30(7) of the Regulations and therefore, disclosure of all such events shall be made to the Stock Exchange under provisions of Regulation 4(1) and 30 of the Regulations.

Considering the aforesaid, the Company is hereby advised to be careful in future to avoid recurrence of such lapses and exercise due diligence while submitting disclosures to the Stock Exchange. You are requested to ensure that the Company files relevant and adequate information regarding material events / incidents impacting the Company in compliance with the Regulations not only in letter but in spirit. Filing incomplete information or delay in disclosing the details as

This Document is Digitally Signed



Signer: DHAVAL SHAH  
Date: Wed, Jun 14, 2023 20:00:26 IST  
Location: NSE



## National Stock Exchange Of India Limited

required under the Regulations in future, would attract suitable disciplinary action, as may be deemed fit.

You are advised to place this letter before the Company's Board of Directors in the upcoming board meeting and disseminate the letter to the Stock Exchanges.

Yours faithfully,  
For **National Stock Exchange of India Limited**

**Dhaval Shah**  
Manager

This Document is Digitally Signed

Signer: DHAVAL SHAH  
Date: Wed, Jun 14, 2023 20:00:26 IST  
Location: NSE

